ArticleJournal of market access & health policy2025

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK.

Nichola Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.